Table 5. . Characteristics of patients with and without immune-mediated adverse event.
Patient characteristics | Affected (n = 15) | Not affected (n = 36) | p-value |
---|---|---|---|
Age | 64.5 | 63.6 | 0.846 |
Gender | 73.3% | 75.0% | 0.906 |
Overall survival (median) | 20.6 months; 95% CI: 10.9–30.3 |
11.1 months; 95% CI: 7.8–14.5 |
0.030 |
Progression-free survival (median) | 16.7 months; 95% CI: 6.9–26.6 |
6.38 months; 95% CI: 3.7–9.1 |
0.041 |